Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Single Arm, Belumosudil and Ruxolitinib Combination 3rd Line Therapy After 2nd Line Ruxolitinib Failure for Chronic Graft vs Host Disease (cGvHD) Treatment (BELRUX)

NCT07643025 is registered in ClinicalTrials.gov with Dennis Kim as lead sponsor.

NCT NCT07643025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07643025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Single Arm, Belumosudil and Ruxolitinib Combination 3rd Line Therapy After 2nd Line Ruxolitinib Failure for Chronic Graft vs Host Disease (cGvHD) Treatment (BELRUX)
Lead sponsor
Dennis Kim
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 30, 2030
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cgvhd